With the approval of the genetic drug Tofersen (for mutations in the SOD1 gene) and studies on new drugs (for mutations in FUS, TARDBP and C9orf72), genetic diagnostics are becoming increasingly important. Genetic changes in the SOD1, C9orf72, FUS and TARDBP genes are present in 14% of all people with ALS – in 2.5 %
in the SOD1 gene. For ALS patients who are not being cared for in an ALS outpatient clinic or do not have direct access to a laboratory for ALS genetics, organizational support is provided by the ALS Genetics Program of Ambulanzpartner.
It’s so easy to take part
Do you have questions about the ALS genetics program? I will be happy to help you!
Peggy Schumann
Medical research